drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01406 | DB06626 | 984 | 263 | [
"DDInter472",
"DDInter147"
] | Danazol | Axitinib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
984,
24,
263
]
],
[
[
984,
63,
322
],
[
322,
24,
263
]
],
[
[
984,
24,
1593
],
[
1593,
63,
263
]
],
[
[
984,
24,
1250
],
[
1250,
... | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epi... | Danazol may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may... |
DB01182 | DB09268 | 371 | 1,662 | [
"DDInter1534",
"DDInter1464"
] | Propafenone | Picosulfuric acid | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
371,
24,
1662
]
],
[
[
371,
24,
484
],
[
484,
63,
1662
]
],
[
[
371,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
371,
63,
597
],
[
597,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Propafenone may lead to a major life threatening interaction when taken with Cabozantinib and Cabozant... |
DB00927 | DB01067 | 1,559 | 959 | [
"DDInter712",
"DDInter826"
] | Famotidine | Glipizide | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1559,
24,
959
]
],
[
[
1559,
63,
245
],
[
245,
40,
959
]
],
[
[
1559,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1559,
18,
1918
],
[
1918,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB01202 | DB04837 | 1,435 | 649 | [
"DDInter1046",
"DDInter407"
] | Levetiracetam | Clofedanol | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1435,
24,
649
]
],
[
[
1435,
63,
1376
],
[
1376,
24,
649
]
],
[
[
1435,
63,
832
],
[
832,
40,
649
]
],
[
[
1435,
24,
820
],
[
820,
... | [
[
[
"Levetiracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Levetiracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Levetiracetam may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Levetiracetam may cause a moderate interaction that could exacerbate diseases when taken with Tripe... |
DB00405 | DB00964 | 128 | 1,617 | [
"DDInter517",
"DDInter110"
] | Dexbrompheniramine | Apraclonidine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Moderate | 1 | [
[
[
128,
24,
1617
]
],
[
[
128,
24,
1020
],
[
1020,
1,
1617
]
],
[
[
128,
24,
1084
],
[
1084,
40,
1617
]
],
[
[
128,
24,
222
],
[
222,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidin... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Apraclonidine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Aprac... |
DB00005 | DB08860 | 1,057 | 788 | [
"DDInter687",
"DDInter1479"
] | Etanercept | Pitavastatin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
1057,
24,
788
]
],
[
[
1057,
24,
671
],
[
671,
1,
788
]
],
[
[
1057,
24,
700
],
[
700,
40,
788
]
],
[
[
1057,
24,
126
],
[
126,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (... |
DB12240 | DB12500 | 110 | 283 | [
"DDInter1485",
"DDInter714"
] | Polatuzumab vedotin | Fedratinib | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
110,
24,
283
]
],
[
[
110,
63,
351
],
[
351,
23,
283
]
],
[
[
110,
63,
1419
],
[
1419,
24,
283
]
],
[
[
110,
25,
676
],
[
676,
6... | [
[
[
"Polatuzumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Polatuzumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribocicli... | Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Imati... |
DB00220 | DB08907 | 798 | 1,344 | [
"DDInter1276",
"DDInter280"
] | Nelfinavir | Canagliflozin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
798,
24,
1344
]
],
[
[
798,
24,
549
],
[
549,
1,
1344
]
],
[
[
798,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
798,
21,
28873
],
[
28873,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nelfinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Nelfinavir (Compound) causes Pancreatitis (Side Effect) ... |
DB01115 | DB08899 | 336 | 129 | [
"DDInter1291",
"DDInter649"
] | Nifedipine | Enzalutamide | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
336,
25,
129
]
],
[
[
336,
6,
8374
],
[
8374,
45,
129
]
],
[
[
336,
21,
28703
],
[
28703,
60,
129
]
],
[
[
336,
63,
1512
],
[
1512,
... | [
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzal... | Nifedipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Nifedipine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Di... |
DB00022 | DB06772 | 268 | 310 | [
"DDInter1408",
"DDInter259"
] | Peginterferon alfa-2b | Cabazitaxel | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
268,
24,
310
]
],
[
[
268,
24,
973
],
[
973,
24,
310
]
],
[
[
268,
25,
139
],
[
139,
24,
310
]
],
[
[
268,
63,
1451
],
[
1451,
2... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pacl... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Zidovudine an... |
DB00443 | DB11627 | 251 | 1,367 | [
"DDInter195",
"DDInter860"
] | Betamethasone | Hepatitis B Vaccine (Recombinant) | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
251,
24,
1367
]
],
[
[
251,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
251,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
251,
24,
259
],
[
259,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Betamethasone may lead to a major life threatening interaction when taken with Cladr... |
DB00959 | DB06717 | 1,486 | 875 | [
"DDInter1191",
"DDInter778"
] | Methylprednisolone | Fosaprepitant | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
1486,
24,
875
]
],
[
[
1486,
63,
723
],
[
723,
1,
875
]
],
[
[
1486,
21,
29180
],
[
29180,
60,
875
]
],
[
[
1486,
63,
1101
],
[
1101,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepita... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Methylprednisolone (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
... |
DB08870 | DB12674 | 850 | 975 | [
"DDInter228",
"DDInter1105"
] | Brentuximab vedotin | Lurbinectedin | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
850,
24,
975
]
],
[
[
850,
63,
1488
],
[
1488,
24,
975
]
],
[
[
850,
24,
1613
],
[
1613,
24,
975
]
],
[
[
850,
24,
159
],
[
159,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludar... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00322 | DB00888 | 141 | 1,001 | [
"DDInter742",
"DDInter1133"
] | Floxuridine | Mechlorethamine | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Moderate | 1 | [
[
[
141,
24,
1001
]
],
[
[
141,
24,
450
],
[
450,
1,
1001
]
],
[
[
141,
21,
28725
],
[
28725,
60,
1001
]
],
[
[
141,
23,
255
],
[
255,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Floxuridine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Mechlorethamine (Compound)
Floxuridine ma... |
DB00290 | DB10315 | 329 | 1,137 | [
"DDInter219",
"DDInter1127"
] | Bleomycin | Measles virus vaccine live attenuated | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
329,
25,
1137
]
],
[
[
329,
64,
581
],
[
581,
25,
1137
]
],
[
[
329,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
329,
24,
141
],
[
141,
... | [
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"... | Bleomycin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may ... |
DB00445 | DB00467 | 322 | 1,467 | [
"DDInter655",
"DDInter644"
] | Epirubicin | Enoxacin | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Minor | 0 | [
[
[
322,
23,
1467
]
],
[
[
322,
24,
1539
],
[
1539,
40,
1467
]
],
[
[
322,
23,
1299
],
[
1299,
1,
1467
]
],
[
[
322,
64,
1176
],
[
1176,
... | [
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin (Compound) resembles Enoxacin (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Enoxacin (Compound)
Ep... |
DB00694 | DB09078 | 51 | 1,228 | [
"DDInter485",
"DDInter1036"
] | Daunorubicin | Lenvatinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
51,
24,
1228
]
],
[
[
51,
23,
112
],
[
112,
23,
1228
]
],
[
[
51,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
51,
24,
938
],
[
938,
63... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and... |
DB01001 | DB01365 | 688 | 280 | [
"DDInter1632",
"DDInter1151"
] | Salbutamol | Mephentermine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
688,
24,
280
]
],
[
[
688,
63,
551
],
[
551,
1,
280
]
],
[
[
688,
63,
80
],
[
80,
40,
280
]
],
[
[
688,
24,
1161
],
[
1161,
1,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Mephentermine (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Mephentermine (Co... |
DB01045 | DB01259 | 463 | 392 | [
"DDInter1590",
"DDInter1024"
] | Rifampicin | Lapatinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
463,
24,
392
]
],
[
[
463,
6,
4973
],
[
4973,
45,
392
]
],
[
[
463,
25,
1135
],
[
1135,
62,
392
]
],
[
[
463,
63,
112
],
[
112,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifampicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Rifampicin may cause a moderate interacti... |
DB00776 | DB01619 | 1,335 | 830 | [
"DDInter1360",
"DDInter1441"
] | Oxcarbazepine | Phenindamine | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1335,
24,
830
]
],
[
[
1335,
24,
537
],
[
537,
40,
830
]
],
[
[
1335,
40,
114
],
[
114,
1,
830
]
],
[
[
1335,
63,
1219
],
[
1219,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Oxcarbazepine (Compound) resembles Nortriptyline (Compound) and Nortriptyline (Compound) resembles Phenindamine (Compound)
Oxcarbazepine may cause a moderate... |
DB00013 | DB09075 | 1,255 | 498 | [
"DDInter1905",
"DDInter621"
] | Urokinase | Edoxaban | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1255,
25,
498
]
],
[
[
1255,
23,
944
],
[
944,
62,
498
]
],
[
[
1255,
24,
1004
],
[
1004,
63,
498
]
],
[
[
1255,
24,
41
],
[
41,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl sa... |
DB00783 | DB01278 | 1,438 | 1,021 | [
"DDInter679",
"DDInter1506"
] | Estradiol | Pramlintide | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1438,
24,
1021
]
],
[
[
1438,
1,
380
],
[
380,
24,
1021
]
],
[
[
1438,
24,
708
],
[
708,
63,
1021
]
],
[
[
1438,
1,
35
],
[
35,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Estradiol",
"{u} (Compound) resembles {v} (Compound)",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} ... | Estradiol (Compound) resembles Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a modera... |
DB01045 | DB08870 | 463 | 850 | [
"DDInter1590",
"DDInter228"
] | Rifampicin | Brentuximab vedotin | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
463,
24,
850
]
],
[
[
463,
63,
267
],
[
267,
24,
850
]
],
[
[
463,
25,
1033
],
[
1033,
63,
850
]
],
[
[
463,
24,
1468
],
[
1468,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Rifampicin may lead to a major life threatening interaction when taken with Alpelisib and Alpelisib may... |
DB00063 | DB03619 | 366 | 557 | [
"DDInter659",
"DDInter501"
] | Eptifibatide | Deoxycholic acid | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Moderate | 1 | [
[
[
366,
24,
557
]
],
[
[
366,
24,
1479
],
[
1479,
24,
557
]
],
[
[
366,
25,
126
],
[
126,
24,
557
]
],
[
[
366,
25,
405
],
[
405,
6... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic a... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid
Eptifibatide may lead to a major life threatening interaction when taken with Warfar... |
DB01203 | DB01362 | 699 | 497 | [
"DDInter1255",
"DDInter960"
] | Nadolol | Iohexol | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
699,
24,
497
]
],
[
[
699,
24,
258
],
[
258,
40,
497
]
],
[
[
699,
21,
28787
],
[
28787,
60,
497
]
],
[
[
699,
24,
1013
],
[
1013,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
"Iodix... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Nadolol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iohexol (Compound)
Nadolol may cause a moderate interaction that could exac... |
DB08881 | DB11718 | 868 | 927 | [
"DDInter1925",
"DDInter640"
] | Vemurafenib | Encorafenib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
868,
25,
927
]
],
[
[
868,
62,
112
],
[
112,
23,
927
]
],
[
[
868,
24,
720
],
[
720,
24,
927
]
],
[
[
868,
64,
216
],
[
216,
24,... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB04844 | DB11186 | 843 | 1,609 | [
"DDInter1778",
"DDInter1427"
] | Tetrabenazine | Pentoxyverine | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
843,
24,
1609
]
],
[
[
843,
64,
104
],
[
104,
24,
1609
]
],
[
[
843,
63,
649
],
[
649,
24,
1609
]
],
[
[
843,
24,
849
],
[
849,
... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
],
[
... | Tetrabenazine may lead to a major life threatening interaction when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedan... |
DB00862 | DB11978 | 1,005 | 124 | [
"DDInter1918",
"DDInter822"
] | Vardenafil | Glasdegib | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1005,
24,
124
]
],
[
[
1005,
24,
112
],
[
112,
23,
124
]
],
[
[
1005,
63,
79
],
[
79,
24,
124
]
],
[
[
1005,
24,
688
],
[
688,
2... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sora... |
DB01253 | DB11979 | 628 | 1,320 | [
"DDInter664",
"DDInter625"
] | Ergometrine | Elagolix | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
628,
24,
1320
]
],
[
[
628,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
628,
24,
484
],
[
484,
63,
1320
]
],
[
[
628,
63,
597
],
[
597,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and E... |
DB01193 | DB06791 | 819 | 1,446 | [
"DDInter12",
"DDInter1021"
] | Acebutolol | Lanreotide | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
819,
24,
1446
]
],
[
[
819,
40,
887
],
[
887,
24,
1446
]
],
[
[
819,
24,
549
],
[
549,
24,
1446
]
],
[
[
819,
63,
1685
],
[
1685,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate in... | Acebutolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that cou... |
DB09030 | DB12500 | 840 | 283 | [
"DDInter1945",
"DDInter714"
] | Vorapaxar | Fedratinib | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
840,
25,
283
]
],
[
[
840,
63,
885
],
[
885,
24,
283
]
],
[
[
840,
64,
932
],
[
932,
24,
283
]
],
[
[
840,
24,
179
],
[
179,
24,... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprosten... | Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Vorapaxar may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may ... |
DB00283 | DB01041 | 701 | 770 | [
"DDInter395",
"DDInter1789"
] | Clemastine | Thalidomide | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
701,
24,
770
]
],
[
[
701,
21,
28784
],
[
28784,
60,
770
]
],
[
[
701,
24,
849
],
[
849,
63,
770
]
],
[
[
701,
24,
1533
],
[
1533,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side ... | Clemastine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Thalidomide (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when tak... |
DB00363 | DB11978 | 695 | 124 | [
"DDInter419",
"DDInter822"
] | Clozapine | Glasdegib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
695,
25,
124
]
],
[
[
695,
23,
112
],
[
112,
23,
124
]
],
[
[
695,
64,
475
],
[
475,
24,
124
]
],
[
[
695,
25,
79
],
[
79,
24,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Clozapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a mod... |
DB00261 | DB01045 | 702 | 463 | [
"DDInter93",
"DDInter1590"
] | Anagrelide | Rifampicin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
702,
24,
463
]
],
[
[
702,
6,
7950
],
[
7950,
45,
463
]
],
[
[
702,
25,
1264
],
[
1264,
62,
463
]
],
[
[
702,
25,
1166
],
[
1166,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Rifampicin (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Anagrelide may lead to a major life threa... |
DB00393 | DB00586 | 854 | 1,512 | [
"DDInter1295",
"DDInter537"
] | Nimodipine | Diclofenac | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
854,
24,
1512
]
],
[
[
854,
6,
8374
],
[
8374,
45,
1512
]
],
[
[
854,
21,
29231
],
[
29231,
60,
1512
]
],
[
[
854,
24,
752
],
[
752,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound)
Nimodipine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Cimet... |
DB08816 | DB12001 | 578 | 564 | [
"DDInter1802",
"DDInter7"
] | Ticagrelor | Abemaciclib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
578,
24,
564
]
],
[
[
578,
63,
536
],
[
536,
24,
564
]
],
[
[
578,
24,
868
],
[
868,
24,
564
]
],
[
[
578,
24,
982
],
[
982,
63,... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and ... |
DB00468 | DB12130 | 1,424 | 1,017 | [
"DDInter1557",
"DDInter1094"
] | Quinine | Lorlatinib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1424,
24,
1017
]
],
[
[
1424,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1424,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1424,
63,
590
],
[
590... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene m... |
DB00682 | DB06605 | 126 | 1,409 | [
"DDInter1951",
"DDInter108"
] | Warfarin | Apixaban | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
126,
25,
1409
]
],
[
[
126,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
126,
23,
539
],
[
539,
62,
1409
]
],
[
[
126,
35,
307
],
[
307,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
... | Warfarin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Warfarin (Compound) resembles Moda... |
DB01067 | DB01246 | 959 | 820 | [
"DDInter826",
"DDInter45"
] | Glipizide | Alimemazine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
959,
24,
820
]
],
[
[
959,
63,
104
],
[
104,
40,
820
]
],
[
[
959,
24,
401
],
[
401,
24,
820
]
],
[
[
959,
63,
939
],
[
939,
24,... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB01110 | DB01115 | 86 | 336 | [
"DDInter1209",
"DDInter1291"
] | Miconazole | Nifedipine | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
86,
24,
336
]
],
[
[
86,
63,
1428
],
[
1428,
1,
336
]
],
[
[
86,
63,
1081
],
[
1081,
40,
336
]
],
[
[
86,
6,
7950
],
[
7950,
45,... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Compound... |
DB01175 | DB08901 | 318 | 1,468 | [
"DDInter672",
"DDInter1492"
] | Escitalopram | Ponatinib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
318,
24,
1468
]
],
[
[
318,
25,
478
],
[
478,
24,
1468
]
],
[
[
318,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
318,
18,
7623
],
[
7623,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotini... | Escitalopram may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Escitalopram (Compound) downregul... |
DB00704 | DB00749 | 267 | 59 | [
"DDInter1263",
"DDInter699"
] | Naltrexone | Etodolac | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
267,
24,
59
]
],
[
[
267,
21,
29093
],
[
29093,
60,
59
]
],
[
[
267,
63,
372
],
[
372,
24,
59
]
],
[
[
267,
24,
848
],
[
848,
63... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Naltrexone",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by ... | Naltrexone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Etodolac (Compound)
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Etodolac
Na... |
DB00374 | DB00457 | 1,061 | 1,205 | [
"DDInter1852",
"DDInter1511"
] | Treprostinil | Prazosin | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | Moderate | 1 | [
[
[
1061,
24,
1205
]
],
[
[
1061,
24,
195
],
[
195,
1,
1205
]
],
[
[
1061,
63,
472
],
[
472,
1,
1205
]
],
[
[
1061,
18,
16662
],
[
16662,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
],
[
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Terazosin and Terazosin (Compound) resembles Prazosin (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Alfuzosin and Alfuzosin (Compound) resembles Prazosin (Compound)
Trep... |
DB06228 | DB09293 | 792 | 116 | [
"DDInter1609",
"DDInter954"
] | Rivaroxaban | Iodide I-131 | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
792,
24,
116
]
],
[
[
792,
63,
1249
],
[
1249,
24,
116
]
],
[
[
792,
24,
1004
],
[
1004,
63,
116
]
],
[
[
792,
25,
365
],
[
365,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate a... |
DB00031 | DB08875 | 20 | 1,618 | [
"DDInter1764",
"DDInter262"
] | Tenecteplase | Cabozantinib | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
20,
25,
1618
]
],
[
[
20,
24,
41
],
[
41,
63,
1618
]
],
[
[
20,
24,
222
],
[
222,
24,
1618
]
],
[
[
20,
24,
885
],
[
885,
25,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibut... |
DB01203 | DB01284 | 699 | 1,042 | [
"DDInter1255",
"DDInter1782"
] | Nadolol | Tetracosactide | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
699,
24,
1042
]
],
[
[
699,
64,
455
],
[
455,
23,
1042
]
],
[
[
699,
75,
688
],
[
688,
23,
1042
]
],
[
[
699,
63,
1148
],
[
1148,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Nadolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",... | Nadolol may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Nadolol (Compound) resembles Salbutamol (Compound) and Nadolol may lead to a major life threatening interaction when taken with ... |
DB01043 | DB01114 | 108 | 272 | [
"DDInter1146",
"DDInter362"
] | Memantine | Chlorpheniramine | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
108,
24,
272
]
],
[
[
108,
24,
849
],
[
849,
63,
272
]
],
[
[
108,
63,
128
],
[
128,
24,
272
]
],
[
[
108,
6,
8803
],
[
8803,
45... | [
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Memantine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramin... |
DB01234 | DB01319 | 1,220 | 34 | [
"DDInter513",
"DDInter777"
] | Dexamethasone | Fosamprenavir | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1220,
24,
34
]
],
[
[
1220,
63,
1091
],
[
1091,
40,
34
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
34
]
],
[
[
1220,
21,
28835
],
[
28835,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Dexamethasone (Compound) causes Hyperglycaemia (Side E... |
DB00651 | DB01359 | 746 | 729 | [
"DDInter613",
"DDInter1417"
] | Dyphylline | Penbutolol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Major | 2 | [
[
[
746,
25,
729
]
],
[
[
746,
64,
461
],
[
461,
1,
729
]
],
[
[
746,
25,
699
],
[
699,
40,
729
]
],
[
[
746,
21,
28698
],
[
28698,
... | [
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Penbutolol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} (Compou... | Dyphylline may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Dyphylline may lead to a major life threatening interaction when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Dyphylline (Compound) causes Insomnia (Sid... |
DB00490 | DB01259 | 946 | 392 | [
"DDInter254",
"DDInter1024"
] | Buspirone | Lapatinib | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
946,
24,
392
]
],
[
[
946,
6,
4973
],
[
4973,
45,
392
]
],
[
[
946,
21,
28674
],
[
28674,
60,
392
]
],
[
[
946,
24,
723
],
[
723,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Buspirone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Buspirone (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apr... |
DB06688 | DB15719 | 1,430 | 487 | [
"DDInter1677",
"DDInter171"
] | Sipuleucel-T | Belantamab mafodotin | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufa... | Moderate | 1 | [
[
[
1430,
24,
487
]
],
[
[
1430,
63,
259
],
[
259,
24,
487
]
],
[
[
1430,
24,
713
],
[
713,
24,
487
]
],
[
[
1430,
24,
976
],
[
976,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Dimethy... |
DB00673 | DB15035 | 723 | 503 | [
"DDInter112",
"DDInter1959"
] | Aprepitant | Zanubrutinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
723,
25,
503
]
],
[
[
723,
25,
982
],
[
982,
24,
503
]
],
[
[
723,
24,
868
],
[
868,
24,
503
]
],
[
[
723,
23,
222
],
[
222,
24,... | [
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u}... | Aprepitant may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may ca... |
DB00350 | DB08907 | 1,214 | 1,344 | [
"DDInter1226",
"DDInter280"
] | Minoxidil | Canagliflozin | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1214,
24,
1344
]
],
[
[
1214,
24,
549
],
[
549,
1,
1344
]
],
[
[
1214,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
1214,
25,
1150
],
[
1150,... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate... |
DB00286 | DB04868 | 380 | 478 | [
"DDInter439",
"DDInter1293"
] | Conjugated estrogens | Nilotinib | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
380,
24,
478
]
],
[
[
380,
6,
4973
],
[
4973,
45,
478
]
],
[
[
380,
7,
8587
],
[
8587,
46,
478
]
],
[
[
380,
21,
28963
],
[
28963,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by... | Conjugated estrogens (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Conjugated estrogens (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Nilotinib (Compound)
Conjugated estrogens (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotini... |
DB00637 | DB01242 | 1,557 | 1,237 | [
"DDInter128",
"DDInter410"
] | Astemizole | Clomipramine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1557,
24,
1237
]
],
[
[
1557,
25,
684
],
[
684,
1,
1237
]
],
[
[
1557,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
1557,
63,
216
],
[
216,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thiori... | Astemizole may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Ast... |
DB04845 | DB13007 | 309 | 1,060 | [
"DDInter1001",
"DDInter642"
] | Ixabepilone | Enfortumab vedotin | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
309,
24,
1060
]
],
[
[
309,
24,
129
],
[
129,
23,
1060
]
],
[
[
309,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
309,
63,
14
],
[
14,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Crizotini... |
DB00529 | DB01142 | 789 | 1,264 | [
"DDInter779",
"DDInter593"
] | Foscarnet | Doxepin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
789,
24,
1264
]
],
[
[
789,
24,
401
],
[
401,
24,
1264
]
],
[
[
789,
21,
29226
],
[
29226,
60,
1264
]
],
[
[
789,
23,
112
],
[
112,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Foscarnet (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Doxepin (Compound)
... |
DB06822 | DB15035 | 802 | 503 | [
"DDInter1812",
"DDInter1959"
] | Tinzaparin | Zanubrutinib | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
802,
25,
503
]
],
[
[
802,
63,
222
],
[
222,
24,
503
]
],
[
[
802,
24,
738
],
[
738,
24,
503
]
],
[
[
802,
64,
39
],
[
39,
25,
... | [
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Tinzaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nir... |
DB00687 | DB01339 | 870 | 728 | [
"DDInter747",
"DDInter1922"
] | Fludrocortisone | Vecuronium | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide ad... | Moderate | 1 | [
[
[
870,
24,
728
]
],
[
[
870,
24,
1610
],
[
1610,
1,
728
]
],
[
[
870,
24,
1579
],
[
1579,
40,
728
]
],
[
[
870,
21,
29644
],
[
29644,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium... |
DB09280 | DB14568 | 1,604 | 982 | [
"DDInter1101",
"DDInter1000"
] | Lumacaftor | Ivosidenib | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1604,
25,
982
]
],
[
[
1604,
64,
168
],
[
168,
23,
982
]
],
[
[
1604,
64,
976
],
[
976,
24,
982
]
],
[
[
1604,
63,
628
],
[
628,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} m... | Lumacaftor may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Lumacaftor may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate inte... |
DB09065 | DB12141 | 760 | 971 | [
"DDInter424",
"DDInter817"
] | Cobicistat | Gilteritinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
760,
25,
971
]
],
[
[
760,
64,
1135
],
[
1135,
23,
971
]
],
[
[
760,
24,
466
],
[
466,
62,
971
]
],
[
[
760,
63,
1335
],
[
1335,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Cobicistat may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may caus... |
DB00436 | DB00572 | 323 | 85 | [
"DDInter179",
"DDInter136"
] | Bendroflumethiazide | Atropine | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Minor | 0 | [
[
[
323,
23,
85
]
],
[
[
323,
62,
19
],
[
19,
24,
85
]
],
[
[
323,
25,
1166
],
[
1166,
40,
85
]
],
[
[
323,
21,
28722
],
[
28722,
60... | [
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atropine"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyoscyamine"
... | Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Bendroflumethiazide may lead to a major life threatening interaction when taken with Dolasetron and Dolas... |
DB00877 | DB01200 | 629 | 469 | [
"DDInter1678",
"DDInter243"
] | Sirolimus | Bromocriptine | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
629,
24,
469
]
],
[
[
629,
63,
826
],
[
826,
1,
469
]
],
[
[
629,
24,
628
],
[
628,
1,
469
]
],
[
[
629,
6,
8374
],
[
8374,
45,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergotamine"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ergotamine and Ergotamine (Compound) resembles Bromocriptine (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ergometrine and Ergometrine (Compound) resembles Bromocriptine (Comp... |
DB09082 | DB11986 | 659 | 484 | [
"DDInter1934",
"DDInter648"
] | Vilanterol | Entrectinib | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
659,
24,
484
]
],
[
[
659,
63,
222
],
[
222,
23,
484
]
],
[
[
659,
63,
1539
],
[
1539,
24,
484
]
],
[
[
659,
24,
180
],
[
180,
6... | [
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxa... |
DB00574 | DB12364 | 121 | 1,421 | [
"DDInter717",
"DDInter200"
] | Fenfluramine | Betrixaban | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
121,
24,
1421
]
],
[
[
121,
64,
529
],
[
529,
24,
1421
]
],
[
[
121,
25,
41
],
[
41,
24,
1421
]
],
[
[
121,
24,
1339
],
[
1339,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvo... | Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may cause... |
DB00277 | DB00341 | 1,031 | 1,242 | [
"DDInter1791",
"DDInter343"
] | Theophylline | Cetirizine | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Minor | 0 | [
[
[
1031,
23,
1242
]
],
[
[
1031,
24,
851
],
[
851,
63,
1242
]
],
[
[
1031,
7,
5415
],
[
5415,
46,
1242
]
],
[
[
1031,
21,
28900
],
[
2890... | [
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cetirizine"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Theophylline (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Cetirizine (Compound)
Th... |
DB00460 | DB00975 | 612 | 1,317 | [
"DDInter1929",
"DDInter573"
] | Verteporfin | Dipyridamole | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
612,
24,
1317
]
],
[
[
612,
21,
28748
],
[
28748,
60,
1317
]
],
[
[
612,
24,
714
],
[
714,
63,
1317
]
],
[
[
612,
63,
942
],
[
942,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caus... | Verteporfin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Dipyridamole (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamol... |
DB00445 | DB08880 | 322 | 1,510 | [
"DDInter655",
"DDInter1771"
] | Epirubicin | Teriflunomide | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
322,
25,
1510
]
],
[
[
322,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
322,
24,
129
],
[
129,
63,
1510
]
],
[
[
322,
24,
1136
],
[
1136,
... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzal... |
DB00436 | DB00747 | 323 | 1,442 | [
"DDInter179",
"DDInter1647"
] | Bendroflumethiazide | Scopolamine | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Minor | 0 | [
[
[
323,
23,
1442
]
],
[
[
323,
62,
19
],
[
19,
24,
1442
]
],
[
[
323,
21,
28766
],
[
28766,
60,
1442
]
],
[
[
323,
40,
504
],
[
504,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Scopolamine"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyoscyamine"... | Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Bendroflumethiazide (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is cause... |
DB00015 | DB09228 | 582 | 687 | [
"DDInter1585",
"DDInter437"
] | Reteplase | Conestat alfa | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibi... | Moderate | 1 | [
[
[
582,
24,
687
]
],
[
[
582,
23,
1631
],
[
1631,
62,
20
],
[
20,
24,
687
]
],
[
[
582,
24,
758
],
[
758,
63,
20
],
[
20,
24,
687... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conestat alfa"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Reteplas... |
DB06674 | DB11767 | 908 | 1,583 | [
"DDInter837",
"DDInter1643"
] | Golimumab | Sarilumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Major | 2 | [
[
[
908,
25,
1583
]
],
[
[
908,
62,
1461
],
[
1461,
23,
1583
]
],
[
[
908,
23,
1114
],
[
1114,
23,
1583
]
],
[
[
908,
63,
362
],
[
362,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sarilumab
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate ma... |
DB01087 | DB09080 | 1,520 | 144 | [
"DDInter1520",
"DDInter1331"
] | Primaquine | Olodaterol | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1520,
24,
144
]
],
[
[
1520,
62,
1247
],
[
1247,
23,
144
]
],
[
[
1520,
63,
956
],
[
956,
24,
144
]
],
[
[
1520,
24,
371
],
[
371,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin a... |
DB00060 | DB00987 | 912 | 1,224 | [
"DDInter947",
"DDInter460"
] | Interferon beta-1a | Cytarabine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Moderate | 1 | [
[
[
912,
24,
1224
]
],
[
[
912,
24,
1176
],
[
1176,
23,
1224
]
],
[
[
912,
24,
322
],
[
322,
24,
1224
]
],
[
[
912,
24,
287
],
[
287,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxaci... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Epi... |
DB06688 | DB13007 | 1,430 | 1,060 | [
"DDInter1677",
"DDInter642"
] | Sipuleucel-T | Enfortumab vedotin | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1430,
24,
1060
]
],
[
[
1430,
24,
270
],
[
270,
24,
1060
]
],
[
[
1430,
63,
58
],
[
58,
24,
1060
]
],
[
[
1430,
24,
1011
],
[
1011,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Aleface... |
DB06688 | DB15044 | 1,430 | 631 | [
"DDInter1677",
"DDInter1738"
] | Sipuleucel-T | Tafasitamab | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytoto... | Moderate | 1 | [
[
[
1430,
24,
631
]
],
[
[
1430,
63,
4
],
[
4,
24,
631
]
],
[
[
1430,
24,
270
],
[
270,
24,
631
]
],
[
[
1430,
24,
976
],
[
976,
25,... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tafasitamab"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccin... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases wh... |
DB00489 | DB01166 | 17 | 477 | [
"DDInter1704",
"DDInter379"
] | Sotalol | Cilostazol | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Major | 2 | [
[
[
17,
25,
477
]
],
[
[
17,
21,
28658
],
[
28658,
60,
477
]
],
[
[
17,
23,
112
],
[
112,
23,
477
]
],
[
[
17,
25,
820
],
[
820,
63,... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Sotalol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Cilostazol (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
So... |
DB08907 | DB14276 | 1,344 | 1,631 | [
"DDInter280",
"DDInter1892"
] | Canagliflozin | Turmeric | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
1344,
24,
1631
]
],
[
[
1344,
63,
473
],
[
473,
24,
1631
]
],
[
[
1344,
40,
549
],
[
549,
24,
1631
]
],
[
[
1344,
24,
1296
],
[
1296,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Turmeric
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interactio... |
DB01097 | DB11817 | 1,377 | 1,259 | [
"DDInter1033",
"DDInter165"
] | Leflunomide | Baricitinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1377,
25,
1259
]
],
[
[
1377,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
1377,
62,
1461
],
[
1461,
23,
1259
]
],
[
[
1377,
64,
1274
],
[
12... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc ... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vi... |
DB00026 | DB00281 | 1,184 | 608 | [
"DDInter94",
"DDInter1066"
] | Anakinra | Lidocaine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anes... | Moderate | 1 | [
[
[
1184,
24,
608
]
],
[
[
1184,
24,
1101
],
[
1101,
62,
608
]
],
[
[
1184,
25,
1510
],
[
1510,
62,
608
]
],
[
[
1184,
24,
362
],
[
362,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Anakinra may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a... |
DB08895 | DB09074 | 976 | 1,362 | [
"DDInter1825",
"DDInter1327"
] | Tofacitinib | Olaparib | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
976,
25,
1362
]
],
[
[
976,
25,
725
],
[
725,
63,
1362
]
],
[
[
976,
64,
896
],
[
896,
24,
1362
]
],
[
[
976,
63,
576
],
[
576,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satralizumab",
"{... | Tofacitinib may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Tofacitinib may lead to a major life threatening interaction when taken with Etoposide and Etoposide may cause a moderate in... |
DB09118 | DB11979 | 1,580 | 1,320 | [
"DDInter1711",
"DDInter625"
] | Stiripentol | Elagolix | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1580,
24,
1320
]
],
[
[
1580,
63,
168
],
[
168,
23,
1320
]
],
[
[
1580,
63,
79
],
[
79,
24,
1320
]
],
[
[
1580,
64,
129
],
[
129,
... | [
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib... |
DB04946 | DB11130 | 924 | 407 | [
"DDInter907",
"DDInter1344"
] | Iloperidone | Opium | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
924,
24,
407
]
],
[
[
924,
63,
662
],
[
662,
24,
407
]
],
[
[
924,
24,
849
],
[
849,
24,
407
]
],
[
[
924,
64,
1264
],
[
1264,
2... | [
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Iloperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Iloperidone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mep... |
DB00286 | DB12010 | 380 | 214 | [
"DDInter439",
"DDInter785"
] | Conjugated estrogens | Fostamatinib | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
380,
24,
214
]
],
[
[
380,
24,
723
],
[
723,
24,
214
]
],
[
[
380,
63,
600
],
[
600,
24,
214
]
],
[
[
380,
24,
1017
],
[
1017,
6... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprep... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00468 | DB00604 | 1,424 | 1,425 | [
"DDInter1557",
"DDInter385"
] | Quinine | Cisapride | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
1424,
25,
1425
]
],
[
[
1424,
25,
924
],
[
924,
64,
1425
]
],
[
[
1424,
6,
21998
],
[
21998,
45,
1425
]
],
[
[
1424,
23,
1247
],
[
124... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may le... | Quinine may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone may lead to a major life threatening interaction when taken with Cisapride
Quinine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cisapride (Compound)
Quinine may cause a minor interactio... |
DB00903 | DB06691 | 1,680 | 849 | [
"DDInter686",
"DDInter1155"
] | Etacrynic acid | Mepyramine | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1680,
24,
849
]
],
[
[
1680,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1680,
24,
1376
],
[
1376,
24,
849
]
],
[
[
1680,
63,
1648
],
[
1648,... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydra... |
DB00238 | DB06410 | 188 | 1,196 | [
"DDInter1285",
"DDInter595"
] | Nevirapine | Doxercalciferol | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
188,
24,
1196
]
],
[
[
188,
24,
1142
],
[
1142,
23,
1196
]
],
[
[
188,
24,
1619
],
[
1619,
63,
1196
]
],
[
[
188,
25,
1017
],
[
1017,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
[... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a minor interaction that can limit clinical effects when taken with Doxercalciferol
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapari... |
DB00218 | DB00331 | 1,176 | 1,645 | [
"DDInter1247",
"DDInter1164"
] | Moxifloxacin | Metformin | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Moderate | 1 | [
[
[
1176,
24,
1645
]
],
[
[
1176,
21,
28714
],
[
28714,
60,
1645
]
],
[
[
1176,
24,
1647
],
[
1647,
23,
1645
]
],
[
[
1176,
1,
1467
],
[
1... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is cau... | Moxifloxacin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Metformin (Compound)
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Metformin
Mo... |
DB00640 | DB08875 | 1,585 | 1,618 | [
"DDInter31",
"DDInter262"
] | Adenosine | Cabozantinib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1585,
25,
1618
]
],
[
[
1585,
24,
688
],
[
688,
24,
1618
]
],
[
[
1585,
63,
322
],
[
322,
25,
1618
]
],
[
[
1585,
24,
888
],
[
888,
... | [
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirub... |
DB00445 | DB06448 | 322 | 171 | [
"DDInter655",
"DDInter1087"
] | Epirubicin | Lonafarnib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
322,
24,
171
]
],
[
[
322,
24,
888
],
[
888,
24,
171
]
],
[
[
322,
23,
112
],
[
112,
24,
171
]
],
[
[
322,
24,
850
],
[
850,
63,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metroni... |
DB00046 | DB01021 | 1,179 | 674 | [
"DDInter940",
"DDInter1861"
] | Insulin lispro | Trichlormethiazide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
1179,
24,
674
]
],
[
[
1179,
24,
1014
],
[
1014,
40,
674
]
],
[
[
1179,
24,
178
],
[
178,
1,
674
]
],
[
[
1179,
24,
964
],
[
964,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazid... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resemble... |
DB00418 | DB09073 | 536 | 951 | [
"DDInter1650",
"DDInter1379"
] | Secobarbital | Palbociclib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
536,
24,
951
]
],
[
[
536,
24,
1476
],
[
1476,
63,
951
]
],
[
[
536,
63,
134
],
[
134,
24,
951
]
],
[
[
536,
24,
578
],
[
578,
2... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and ... |
DB01403 | DB01612 | 9 | 1,637 | [
"DDInter1175",
"DDInter92"
] | Methotrimeprazine | Amyl Nitrite | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
9,
24,
1637
]
],
[
[
9,
63,
475
],
[
475,
24,
1637
]
],
[
[
9,
64,
593
],
[
593,
24,
1637
]
],
[
[
9,
1,
820
],
[
820,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Methotrimeprazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion ... |
DB00653 | DB12147 | 544 | 241 | [
"DDInter1120",
"DDInter661"
] | Magnesium sulfate | Erdafitinib | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
544,
25,
241
]
],
[
[
544,
24,
286
],
[
286,
25,
241
]
],
[
[
544,
63,
1331
],
[
1331,
25,
241
]
],
[
[
544,
24,
1473
],
[
1473,
... | [
[
[
"Magnesium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Erdafitinib
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Erg... |
DB09330 | DB12825 | 985 | 1,375 | [
"DDInter1352",
"DDInter1032"
] | Osimertinib | Lefamulin | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
985,
25,
1375
]
],
[
[
985,
62,
112
],
[
112,
23,
1375
]
],
[
[
985,
24,
159
],
[
159,
63,
1375
]
],
[
[
985,
64,
976
],
[
976,
... | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Osimertinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Osimertinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and ... |
DB01128 | DB04948 | 918 | 1,084 | [
"DDInter204",
"DDInter1083"
] | Bicalutamide | Lofexidine | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
918,
24,
1084
]
],
[
[
918,
62,
112
],
[
112,
23,
1084
]
],
[
[
918,
63,
688
],
[
688,
24,
1084
]
],
[
[
918,
24,
392
],
[
392,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and ... |
DB08904 | DB11003 | 375 | 748 | [
"DDInter342",
"DDInter100"
] | Certolizumab pegol | Anthrax vaccine | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
375,
24,
748
]
],
[
[
375,
64,
322
],
[
322,
24,
748
]
],
[
[
375,
25,
564
],
[
564,
63,
748
]
],
[
[
375,
25,
1480
],
[
1480,
2... | [
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
... | Certolizumab pegol may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Certolizumab pegol may lead to a major life threatening interaction when taken with Abemaciclib and Abemaciclib ma... |
DB00295 | DB01186 | 475 | 107 | [
"DDInter1244",
"DDInter1430"
] | Morphine | Pergolide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
475,
24,
107
]
],
[
[
475,
6,
12523
],
[
12523,
45,
107
]
],
[
[
475,
21,
28757
],
[
28757,
60,
107
]
],
[
[
475,
24,
832
],
[
832,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pergolide (Compound)
Morphine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Pergolide (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelen... |
DB00593 | DB12332 | 1,464 | 1,619 | [
"DDInter695",
"DDInter1626"
] | Ethosuximide | Rucaparib | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1464,
24,
1619
]
],
[
[
1464,
24,
222
],
[
222,
23,
1619
]
],
[
[
1464,
24,
259
],
[
259,
24,
1619
]
],
[
[
1464,
63,
58
],
[
58,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Ril... |
DB00673 | DB01036 | 723 | 211 | [
"DDInter112",
"DDInter1832"
] | Aprepitant | Tolterodine | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Moderate | 1 | [
[
[
723,
24,
211
]
],
[
[
723,
24,
573
],
[
573,
40,
211
]
],
[
[
723,
63,
494
],
[
494,
40,
211
]
],
[
[
723,
6,
10215
],
[
10215,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
],
[... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine and Fesoterodine (Compound) resembles Tolterodine (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Tolterodine (... |
DB00762 | DB09498 | 613 | 810 | [
"DDInter973",
"DDInter1715"
] | Irinotecan | Strontium chloride Sr-89 | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
613,
24,
810
]
],
[
[
613,
63,
1555
],
[
1555,
24,
810
]
],
[
[
613,
24,
869
],
[
869,
24,
810
]
],
[
[
613,
24,
1619
],
[
1619,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topot... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.